Evidence map›Paper›PMID 19429754›Full record

ArticleJournal of medical microbiology2009

Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum beta-lactamase, AmpC and KPC producers.

Mark A Fisher, Paul D Stamper, Kristine M Hujer, Zachary Love, Ann Croft, Samuel Cohen, Robert A Bonomo, Karen C Carroll, Cathy A Petti

Abstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Expert systems in clinical microbiology.Clinical microbiology reviews · 2011
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark A FisherARUP Laboratories, Salt Lake City, UT, USA.
Paul D StamperThe Johns Hopkins Hospital, Baltimore, MD, USA.
Kristine M HujerLouis Stokes VA Medical Center, Cleveland, Ohio, USA.
Zachary LoveCase Western Reserve University, School of Medicine, Cleveland, OH, USA.
Ann CroftARUP Laboratories, Salt Lake City, UT, USA.
Samuel CohenARUP Laboratories, Salt Lake City, UT, USA.
Robert A BonomoCase Western Reserve University, School of Medicine, Cleveland, OH, USA.
Karen C CarrollThe Johns Hopkins Hospital, Baltimore, MD, USA.
Cathy A PettiARUP Laboratories, Salt Lake City, UT, USA.

Funding

Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
NIAID NIH HHS R01 AI063517NIAID NIH HHS R01-AI63517
6 · The paper itself

Abstract

Phenotypic identification of AmpC, KPC and extended-spectrum beta-lactamases (ESBLs) among members of the Enterobacteriaceae remains challenging. This study compared the Phoenix Automated Microbiology System (BD Diagnostics) with the Clinical and Laboratory Standards Institute confirmatory method to identify ESBL production among 200 Escherichia coli and Klebsiella pneumoniae clinical isolates. The Phoenix system misclassified nearly half of the isolates as ESBL-positive, requiring manual testing for confirmation. Inclusion of aztreonam +/- clavulanic acid (CA) and cefpodoxime +/- CA in the testing algorithm increased the ESBL detection rate by 6 %. Boronic acid-based screening identified 24 isolates as AmpC(+), but in a subset of genotypically characterized isolates, appeared to have a high false-positivity rate. PCR screening revealed eight KPC(+) isolates, all of which tested as ESBL(+) or ESBL(+) AmpC(+) by phenotypic methods, but half were reported as carbapenem-susceptible by the Phoenix system. Overall, these results indicate that laboratories should use the Phoenix ESBL results only as an initial screen followed by confirmation with an alternative method.

Indexed as

Escherichia coliKlebsiella pneumoniaeAnti-Bacterial AgentsAutomationBacterial Proteinsbeta-Lactamasesbeta-Lactam Resistancebeta-LactamsDisk Diffusion Antimicrobial TestsHumansMicrobial Sensitivity TestsPhenotypeReagent Kits, DiagnosticAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-LactamsReagent Kits, Diagnostic

Identifiers

PMID19429754
PMCPMC2887552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.